Get the Stockscreener App
20.00
0.15%
0.03
Oculis Holding Ag stock is traded at $20.00, with a volume of 62,167.
It is up +0.15% in the last 24 hours and up +6.44% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$19.97
Open:
$20.24
24h Volume:
62,167
Relative Volume:
0.60
Market Cap:
$1.16B
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-10.02
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
-2.44%
1M Performance:
+6.44%
6M Performance:
+4.41%
1Y Performance:
+18.13%
1-Day Range:
$19.73
$20.34
1-Week Range:
$19.61
$20.97
52-Week Range:
$14.00
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
20.00 | 1.15B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6% - MarketBeat
Wall Street analysts predict a 106.04% upside in Oculis Holding AG (OCS): Here's what you should know - MSN
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS‑05 and PIONEER Program Progress - simplywall.st
Oculis (NASDAQ:OCS) Shares Down 4.3%Time to Sell? - MarketBeat
Net current asset value per share of Oculis Holding AG – FWB:CR5 - TradingView — Track All Markets
Cash per share of Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING – NASDAQ:OCSAW - TradingView — Track All Markets
Why analysts upgrade Oculis Holding AG Equity Warrant stock2025 Buyback Activity & Safe Entry Zone Tips - Улправда
Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS) - simplywall.st
Is Oculis Holding AG (CR5) stock cheap vs fundamentalsQuarterly Market Summary & Daily Technical Forecast Reports - Улправда
Why Oculis Holding AG Equity Warrant stock attracts global investorsMarket Sentiment Summary & Long-Term Growth Stock Strategies - Улправда
Can Oculis Holding AG stock deliver surprise earnings beatMarket Activity Recap & AI Based Buy/Sell Signal Reports - Улправда
How Oculis Holding AG Equity Warrant stock reacts to inflationary pressuresMarket Rally & Low Risk Growth Stock Ideas - Улправда
Take Profit: How Oculis Holding AG Equity Warrant stock benefits from tech adoptionWeekly Market Outlook & Daily Technical Forecast Reports - Улправда
Oculis (NASDAQ:OCS) Given New $40.00 Price Target at Stifel Nicolaus - Defense World
Oculis (NASDAQ:OCS) Now Covered by JPMorgan Chase & Co. - Defense World
Why Oculis Holding AG stock could benefit from AI revolutionJuly 2025 Technicals & Consistent Profit Trade Alerts - Улправда
Should I hold or sell Oculis Holding AG Equity Warrant stock in 2025July 2025 Trends & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Oculis (NASDAQ:OCS) Shares Gap Up on Analyst Upgrade - Defense World
What sentiment indicators say about Oculis Holding AG stock2025 Volume Leaders & Momentum Based Trading Ideas - Улправда
Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress - Investing.com South Africa
Stifel Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Can Oculis Holding AG stock sustain revenue growthDividend Hike & Growth Focused Entry Point Reports - Улправда
Will Oculis Holding AG stock rally after Fed decisionsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade - MarketBeat
Oculis (NASDAQ:OCS) Price Target Raised to $40.00 at Stifel Nicolaus - MarketBeat
JP Morgan Initiates Coverage on OCS with Overweight Rating | OCS Stock News - GuruFocus
Oculis (NASDAQ:OCS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Recap Report: Is Oculis Holding AG Equity Warrant stock undervalued vs historical averages2025 Price Targets & Entry and Exit Point Strategies - Улправда
JPMorgan Initiates Coverage on Oculis Holding AG With Overweight Rating, $38 Price Target - marketscreener.com
Will Oculis Holding AG Equity Warrant stock split attract more investors2025 Earnings Surprises & Risk Adjusted Buy and Sell Alerts - Bölüm Sonu Canavarı
Why Oculis Holding AG Equity Warrant stock could rally in 2025Gold Moves & Free Community Supported Trade Ideas - DonanımHaber
Bank Watch: Can Oculis Holding AG stock deliver surprise earnings beat2025 Volume Leaders & Safe Entry Zone Tips - Улправда
Investment Review: Will Oculis Holding AG Equity Warrant stock maintain momentum in 2025 - ulpravda.ru
Movement Recap: Is Oculis Holding AG Equity Warrant stock positioned well for digital economy2025 Biggest Moves & Long-Term Safe Investment Ideas - Улправда
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2025 Fundamental Recap & Smart Investment Allocation Insights - Улправда
Aug Retail: Why Oculis Holding AG Equity Warrant stock attracts global investorsTrade Ideas & Reliable Trade Execution Plans - Улправда
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyAnalyst Downgrade & Real-Time Sentiment Analysis - Улправда
How Oculis Holding AG Equity Warrant stock reacts to oil pricesPortfolio Risk Summary & Low Risk High Win Rate Stock Picks - Улправда
How Oculis Holding AG stock performs in rate cut cyclesJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - Улправда
Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
(OCS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analyzing ABVC BioPharma (NASDAQ:ABVC) & Oculis (NASDAQ:OCS) - Defense World
Tangible book value per share of Oculis Holding AG – SWB:CR5 - TradingView — Track All Markets
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis (NASDAQ:OCS) Trading Down 6%Should You Sell? - MarketBeat
Wall Street Analysts Predict a 106.04% Upside in Oculis Holding AG (OCS): Here's What You Should Know - Zacks Investment Research
Oculis initiated with an Outperform at LifeSci Capital - MSN
Oculis (NASDAQ:OCS) Trading 7% HigherHere's What Happened - MarketBeat
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):